What this report covers
This report examines the impact of enforcement against the irresponsible advertising of Prostate-Specific Antigen (PSA) home testing kits and prostate supplements on Meta and Google between February and July 2026. It highlights that, while the compliance rate is poor, there has been an encouraging reduction in the overall number of prostate supplement ads after these actions. It also notes an increase in compliance rates for PSA home testing ads.
Key findings
- Using our AI-based Active Ad Monitoring system, we captured 2.73k unique ads for prostate supplements and PSA home testing kits from the advertisers we contacted between February and July 2026.
- Of these, 2.58k ads were flagged for containing potentially non-compliant claims.
- The main issues were prostate supplement ads claiming to prevent, treat or cure prostate-related health issues, and PSA home testing kit ads misleadingly implying that the tests could diagnose cancer without making their limitations clear.
- Compliance for prostate supplement ads remained extremely low, at 0.5% in February and 0.6% in July. However, the number of ads from contacted advertisers fell from a peak of 835 in April to 180 in July.
- Compliance for PSA home testing kit ads increased from 20.0% in February to 64.5% in July.
Compliance action taken
For prostate supplements, the Compliance team contacted 23 advertisers and instructed them to amend or remove their non-compliant ads. Eight agreed to do so, while 15 did not respond but nevertheless removed their ads.
For PSA home tests, the Compliance team contacted eight advertisers and instructed them to amend or remove their non-compliant ads. All eight agreed to amend or remove the ads flagged to them.
CAP Enforcement Reports
CAP Enforcement Reports explain the action CAP takes to address non-compliance in specific sectors. They also show how these actions affect overall compliance rates.
These reports use insights from our AI-based Active Ad Monitoring system to track ads in certain sectors.